Sugi Predict

Sugi Predict / Compounds / SCHEMBL755924

SCHEMBL755924

SCHEMBL755924

CCC(CC)[C@H](N)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC7A5 Q01650 2/20 0.50
▸ SLC1A3 P43003 3/20 0.44
▸ SLC1A2 P43004 3/20 0.44
▸ SLC1A1 P43005 3/20 0.44
▸ LAP3 P28838 1/20 0.40
▸ USP2 O75604 1/20 0.39
▸ SLCO1B1 Q9Y6L6 1/20 0.39
▸ GRIK1 P39086 2/20 0.37
▸ GRIK2 Q13002 2/20 0.37
▸ GLO1 Q04760 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ AKR1A1 P14550 1/20 0.36
▸ CHRM3 P20309 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ HTR2C P28335 1/20 0.36
▸ ADRA1A P35348 1/20 0.36
▸ HRH1 P35367 1/20 0.36
▸ DRD3 P35462 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.36
▸ HDAC1 Q13547 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7420375 1.00 SLC7A5 (0.50) SLC7A5SLC1A3SLC1A2SLC1A1LAP3
SCHEMBL1168875 1.00 SLC7A5 (0.50) SLC7A5SLC1A3SLC1A2SLC1A1LAP3
SCHEMBL28319951 0.97 SLC7A5 (0.48) SLC7A5SLC1A3SLC1A2SLC1A1LAP3
SCHEMBL28319949 0.97 SLC7A5 (0.48) SLC7A5SLC1A3SLC1A2SLC1A1LAP3
SCHEMBL587730 0.87 USP2 (0.45) SLC7A5SLC1A3SLC1A2SLC1A1LAP3
SCHEMBL5319952 0.87 SLC7A5 (0.44) SLC7A5SLC1A3SLC1A2SLC1A1LAP3
SCHEMBL598942 0.87 USP2 (0.45) SLC7A5SLC1A3SLC1A2SLC1A1LAP3
SCHEMBL6739408 0.87 USP2 (0.45) SLC7A5SLC1A3SLC1A2SLC1A1LAP3
SCHEMBL3673862 0.87 USP2 (0.45) SLC7A5SLC1A3SLC1A2SLC1A1LAP3
SCHEMBL19981311 0.87 USP2 (0.45) SLC7A5SLC1A3SLC1A2SLC1A1LAP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800764-B2 PREPARING CHIRALLY PURE S-ENANTIOMERS OF ALPHA -AMINO ACIDS COMPRISING THE STEPS OF: A) PREPARING AN ORGANOMETALLIC REAGENT FROM AN ALKYL HALIDE OF THE FORMULA (R) 2CH(CH2)NCH2X; B) ADDING THE ORGANOMETALLIC REAGENT TO CARBON DIOXIDE TO FORM WYETH 2004-10-05 — — US claimed
EP-1461303-A2 PROCESS FOR THE SYNTHESIS OF CHIRALLY PURE b-AMINO-ALCOHOLS Wyeth (US) 2004-09-29 — — EP claimed
EP-1461332-A2 PRODUCTION OF CHIRALLY PURE ALPHA-AMINO ACIDS AND N-SULFONYL ALPHA-AMINO ACIDS Wyeth (US) 2004-09-29 — — EP claimed
US-6657070-B2 Such as N-((5-chloro-2-thienyl)sulfonyl)-3-ethylnorvaline and 5-chloro-N-((S)-2-ethyl-1-formylbutyl)thiophene-2-sulfonamide via reacting aldehyde, cyanide salt, and alpha-methylbenzylamine WYETH 2003-12-02 — — US claimed
US-20030144531-A1 Process for the synthesis of chirally pure beta-amino-alcohols WYETH (US) 2003-07-31 — — US claimed
WO-2003050062-A2 PRODUCTION OF CHIRALLY PURE α-AMINO ACIDS ADN N-SULFONYL α-AMINO ACIDS WYETH (US) 2003-06-19 — — WO claimed
WO-2003050063-A2 PROCESS FOR THE SYNTHESIS OF CHIRALLY PURE β-AMINO-ALCOHOLS WYETH (US) 2003-06-19 — — WO claimed
EP-0938496-B1 HEPTAPEPTIDE OXYTOCIN ANALOGUES FERRING BV (NL) 2003-06-04 — — EP claimed
US-20030013892-A1 Production of chirally pure alpha-amino acids and N-sulfonyl alpha-amino acids WYETH 2003-01-16 — — US claimed
US-6143722-A TO CONTROLL UTERINE CONTRACTIONS IN TREATING PRETERM LABOR FERRING, B.V. (NL) 2000-11-07 — — US claimed
EP-0938496-A1 HEPTAPEPTIDE OXYTOCIN ANALOGUES FERRING B.V. (NL) 1999-09-01 — — EP claimed
WO-1998023636-A1 HEPTAPEPTIDE OXYTOCIN ANALOGUES FERRING B.V. (NL) 1998-06-04 — — WO claimed
EP-0791012-A1 PEPTIDES EXHIBITING OXYTOCIN ANTAGONISTIC ACTIVITY FERRING B.V. (NL) 1997-08-27 — — EP claimed
CN-1126999-A Peptide compounds having oxytocin antagonist activity FERRING BV (NL) 1996-07-17 — — CN claimed
WO-1995002609-A1 PEPTIDES EXHIBITING OXYTOCIN ANTAGONISTIC ACTIVITY FERRING B.V. (NL) 1995-01-26 — — WO claimed
EP-4724457-A2 RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Rayzebio, Inc. (US) 2026-04-15 — — EP disclosed
EP-4724459-A1 PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF Peptidream Inc (JP) 2026-04-15 — — EP disclosed
WO-1995002609-A1 PEPTIDES EXHIBITING OXYTOCIN ANTAGONISTIC ACTIVITY FERRING B.V. (NL) 1995-01-26 — — WO disclosed
WO-1993018056-A1 ISOSTERIC ANTIHERPES PEPTIDE DERIVATIVES BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1993-09-16 — — WO disclosed
EP-0560267-A1 Isosteric antiherpes peptide derivatives BIO-MEGA/BOEHRINGER INGELHEIM RESEARCH INC. (CA) 1993-09-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144531-A1 Process for the synthesis of chirally pure beta-amino-alcohols ADH1C, ADH1A, ALDH7A1 SLC7A5 30/4885SLC1A3 441/4885SLC1A2 222/4885
US-20030013892-A1 Production of chirally pure alpha-amino acids and N-sulfonyl alpha-amino acids DNPEP, EDNRB, PNMT SLC7A5 16/4885SLC1A3 103/4885SLC1A2 106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.